Can-Fite Completes Patients Enrollment For Pivotal Phase 3 Psoriasis Trial
Can-Fite BioPharma (CANF) said it completed enrollment for the interim analysis of its pivotal Phase 3 trial of piclidenoson in moderate-to-severe plaque psoriasis. The randomized, double-blind study enrolled 247 patients; results are expected Q4 2026–Q1 2027. Co-primary endpoints are PASI 75 and sPGA 0/1 at Week 16. CANF shares closed July 2 at $3.91.
How this was made
The 30-second read
Why it matters
The key new tradable element is the completion of patient enrollment for the interim analysis stage, which advances the timeline toward interim results (expected between Q4 2026 and Q1 2027).
Market read
Enrollment completion reduces execution risk and shifts focus to interim analysis outcomes and the subsequent regulatory clarity path.
What to watch
Investors may be underweighting the risk that interim analysis could lead to protocol modifications, slower-than-expected readout, or a less favorable efficacy signal than the market expects.
Background
Can-Fite’s pivotal Phase 3 study evaluates Piclidenoson (oral A3 adenosine receptor agonist) in moderate-to-severe plaque psoriasis under a protocol agreed with FDA and EMA.
Ticker impact
Can-Fite says it completed patient enrollment for the interim analysis of its pivotal Phase 3 psoriasis trial of Piclidenoson.
Near-term reaction likely modest unless the market had priced in delays; the bigger repricing risk is around interim readout expectations and any subsequent FDA/EMA feedback.
The article provides a concrete trial milestone (enrollment completion) and a defined interim analysis stage, but no efficacy/safety data or regulatory decision is disclosed.
Market effects
Adds incremental momentum to the psoriasis/dermatology pipeline narrative, particularly for oral small-molecule approaches versus biologics.
Primarily impacts US-listed biotech sentiment; limited broader regional spillover expected from a single enrollment milestone.
FDA/EMA protocol alignment underscores global regulatory pathway progress, supporting international investor confidence in the program.
Counterpoint
Enrollment completion is a process milestone; without interim efficacy/safety data, it may not change the probability-weighted outcome enough to drive sustained re-rating.
Key entities
- companyCan-Fite BioPharma Ltd.
US-listed biotech (CANF) advancing Piclidenoson Phase 3 psoriasis program; reports enrollment completion for interim analysis.
- drugPiclidenoson
Oral A3 adenosine receptor agonist being tested in a pivotal Phase 3 trial for plaque psoriasis.
- regulatorFDA
Agreed the protocol for the interim analysis stage of the pivotal Phase 3 trial.
- regulatorEMA
Agreed the protocol for the interim analysis stage of the pivotal Phase 3 trial.
